People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotechnology, Pharmaceuticals, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Adela, Inc. | — | Biotechnology | Series C | $108.5M | $156.3M | 2021 |
| Aegerion Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $48.7M | $622.8M | 2008 |
| Revelar Biotherapeutics, Inc. | — | Biotechnology | Series B | $18.5M | $20.0M | 2021 |
| ThirdLaw Molecular, Inc. | — | Biotechnology | Series A | $5.5M | $16.4M | 2025 |
| Refactor Health, Inc. | — | Healthtech | Pre-Seed | $600K | $5.6M | 2019 |
| Thyron Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $500K | $8.2M | 2022 |
David Scheer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Scheer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Fonteyne | 2 | 5 |
| Stephen Bloch | 1 | 15 |
| Robert Weisskoff | 1 | 12 |
| Paul Brown | 1 | 12 |
| Brian Halak | 1 | 10 |
| Andrew ElBardissi | 1 | 7 |
| David Bonita | 1 | 6 |
| Eric Heil | 1 | 5 |
| Jason Fisherman | 1 | 5 |
| Michele Ollier | 1 | 4 |
| David Arkowitz | 1 | 3 |
| Brett Giroir | 1 | 3 |
| Maneesh Jain | 1 | 2 |
| Lisa Alderson | 1 | 2 |
| Laurence Smith | 1 | 2 |
| Christine Pellizzari | 1 | 2 |
| Peter Farina | 1 | 2 |
| Anne-Renee Hartman | 1 | 1 |
| Karla Jarvis | 1 | 1 |
| Priscilla Huang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.